| Literature DB >> 35510500 |
Thomas Garrigos1,2, Manon Dollat1, Arnaud Magallon1,2, Anaïs Folletet1, Julien Bador1,2, Maryam Abid3, Marlène Amara4, Clémence Beauruelle5,6, Olivier Belmonte7, Pierre Boyer8,9, Emilie Cardot-Martin10, Anne-Gaëlle Cauchie4, Sylvie Colin de Verdière11, Claire Daurel12, Cécile Gaudru13,14, Farida Hamdad15, Geneviève Héry-Arnaud5,6, Baptiste Hoellinger8, Claudie Lamoureux5,6, Marie-Frédérique Lartigue3,16, Damasie Malandain12, Océane Marchand17, Caroline Piau18, Sandrine Picot19, Hélène Revillet13,14,20, Zeina Sabouni17, Catherine Neuwirth1,2, Lucie Amoureux1,2.
Abstract
Achromobacter spp. are nonfermenting Gram-negative bacilli mainly studied among cystic fibrosis (CF) patients. The identification of the 19 species within the genus is time-consuming (nrdA-sequencing), thus data concerning the distribution of the species are limited to specific studies. Recently, we built a database using MALDI-TOF mass spectrometry (MS) (Bruker) that allows rapid and accurate species identification and detection of the multiresistant epidemic clones: A. xylosoxidans ST137 spreading among CF patients in various French and Belgium centers, and A. ruhlandii DES in Denmark. Here, we first assessed whether species identification could be achieved with our database solely by analysis of MS spectra without availability of isolates. Then, we conducted a multicentric study describing the distribution of Achromobacter species and of the clone ST137 among French CF centers. We collected and analyzed with our local database the spectra of Achromobacter isolates from 193 patients (528 samples) from 12 centers during 2020. In total, our approach enabled to conclude for 502/528 samples (95.1%), corresponding to 181 patients. Eleven species were detected, only five being involved in chronic colonization, A. xylosoxidans (86.4%), A. insuavis (9.1%), A. mucicolens (2.3%), A. marplatensis (1.1%) and A. genogroup 3 (1.1%). This study confirmed the high prevalence of A. xylosoxidans in chronic colonizations and the circulation of the clone A. xylosoxidans ST137 in France: four patients in two centers. The present study is the first to report the distribution of Achromobacter species from CF patients samples using retrospective MALDI-TOF/MS data. This easy approach could enable future large-scale epidemiological studies.Entities:
Keywords: Achromobacter; DES; Maldi-TOF; ST137; cystic fibrosis; epidemiology; identification; mass spectrometry
Mesh:
Year: 2022 PMID: 35510500 PMCID: PMC9199411 DOI: 10.1128/jcm.02422-21
Source DB: PubMed Journal: J Clin Microbiol ISSN: 0095-1137 Impact factor: 11.677